- Home
- BOLT vs MIRA Comparison
BOLT vs MIRA Comparison
Compare BOLT & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- MIRA
- Stock Information
- Founded
- BOLT 2015
- MIRA 2020
- Country
- BOLT United States
- MIRA United States
- Employees
- BOLT N/A
- MIRA N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- MIRA Health Care
- Exchange
- BOLT Nasdaq
- MIRA Nasdaq
- Market Cap
- BOLT 16.8M
- MIRA 19.5M
- IPO Year
- BOLT 2021
- MIRA 2023
- Fundamental
- Price
- BOLT $5.69
- MIRA $1.25
- Analyst Decision
- BOLT Buy
- MIRA Strong Buy
- Analyst Count
- BOLT 3
- MIRA 2
- Target Price
- BOLT $50.00
- MIRA $14.00
- AVG Volume (30 Days)
- BOLT 23.5K
- MIRA 168.5K
- Earning Date
- BOLT 08-12-2025
- MIRA 08-12-2025
- Dividend Yield
- BOLT N/A
- MIRA N/A
- EPS Growth
- BOLT N/A
- MIRA N/A
- EPS
- BOLT N/A
- MIRA N/A
- Revenue
- BOLT $3,638,000.00
- MIRA N/A
- Revenue This Year
- BOLT N/A
- MIRA N/A
- Revenue Next Year
- BOLT $24.14
- MIRA N/A
- P/E Ratio
- BOLT N/A
- MIRA N/A
- Revenue Growth
- BOLT N/A
- MIRA N/A
- 52 Week Low
- BOLT $5.20
- MIRA $0.51
- 52 Week High
- BOLT $15.60
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- BOLT 42.69
- MIRA 46.62
- Support Level
- BOLT $5.36
- MIRA $1.15
- Resistance Level
- BOLT $6.07
- MIRA $1.30
- Average True Range (ATR)
- BOLT 0.44
- MIRA 0.08
- MACD
- BOLT -0.01
- MIRA -0.01
- Stochastic Oscillator
- BOLT 25.58
- MIRA 21.43
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.